Discovery of molecular glues for modulating MHC presentation of cancer neoantigens
A preprint reports the discovery of peptide-MHC glues (PMGs), compounds that promote formation of peptide-MHC class I complexes with cancer antigens that are otherwise poorly presented on the cell surface. Crystal structures of the complexes show the compounds stabilize antigen-MHC binding by making simultaneous interactions with both the MHC protein and the antigen peptide. The work targets a core bottleneck in neoantigen medicine: many cancer-specific antigens fail to form complexes with MHC-I, limiting the fraction usable for therapeutic targeting. As presented, this is early-stage chemical biology — discovery plus structural validation — with the implication that a chemical lever on antigen presentation could expand the targetable neoantigen space if it translates beyond structural studies.